mTOR inhibition: a double-edged sword in patients with COVID-19?

• Published in: Human cell : official journal of Human Cell Research Society Vol. 34; no. 2; pp. 698 - 699
• Main Author: Ghasemnejad-Berenji, Morteza
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.03.2021; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Cell Biology; Commentary; Coronaviruses; COVID-19; COVID-19 - drug therapy; COVID-19 - immunology; Drug Repositioning; Gynecology; Humans; Immune system; Immune System - immunology; Immunosuppressive agents; Infections; Life Sciences; Oncology; Pandemics; Protein biosynthesis; Protein turnover; Rapamycin; Reproductive Medicine; Severe acute respiratory syndrome coronavirus 2; Signal transduction; Signal Transduction - genetics; Signal Transduction - physiology; Sirolimus - pharmacology; Sirolimus - therapeutic use; Stem Cells; Surgery; TOR protein; TOR Serine-Threonine Kinases - antagonists & inhibitors; TOR Serine-Threonine Kinases - physiology; COVID-19; mTOR; SARS-CoV-2; Rapamycin; Cell signaling; Immune system

The current COVID-19 is one of the deadliest pandemics in recent decades. In the lack of a specific treatment for this novel infection, knowing the role of cell signaling pathways in the pathogenesis of this infection could be useful in finding effective drugs against this disease. The mammalian or...